FDA’s Tools for Patient Safety Assessment

by | Mar 17, 2021 | FDA, Quality, Regulatory, Safety, Tools

Patient Safety must be at the center point of all operations in the health care industry. Whether it is the manufacturer who is responsible for designing and developing the drug or the device, doctors and nurses administering the drug or the device, or the FDA who is responsible for regulating the use of such products on patients.

March 14th-20th, is celebrated as patient safety awareness week to celebrate everyone involved with providing quality care for patients while keeping them safe and free from harm. On the occasion of Patient Safety Awareness Week, let’s take a look at some of the tools available to the FDA to evaluate the patient safety of drugs and devices and how the FDA uses them to improve patient safety.1

The two mechanisms through which the FDA assesses the safety of drugs or devices on patients is

  • Pre-market review and approval
  • Post-market monitoring

FDA does not develop or routinely test products before granting any type of approval or clearance; however, FDA reviews the results of laboratory, animal, and human clinical tests done by the sponsor companies. Analysis of these test results provides FDA with the assurance that these products are safe for patient’s use.2

Sometimes, there are significant limitations of the pre-market testing performed despite the extensive evaluation of safety and there are residual risks that need to be closely monitored post-market. That is where FDA’s post-market safety monitoring tools are put to use. 2

FDA’s MedWatch program is a platform for reporting serious adverse events and product problems that have an impact on patient safety. FDA uses the data from this source to evaluate any trends, consult with medical practitioners and manufacturers when required, and conduct further epidemiological studies. This allows for evidence-based decision making to improve patient safety.2

In the coming years, there are more tools that the FDA plans on pushing out to protect patient safety such as the expansion of the UDI program, National Evaluation System for Health Technology program, and many more. I am personally looking forward to the expansion and implementation of these programs and to see how it is integrated into the industry.

EMMA International is here to assist you in all of your compliance needs and help you in your path to protect public health. Call us today at +1 248-987-4497 or email us at info@emmainternational.com


1Health.mil (2021) Patient Safety Awareness Week retrieved on 03/14/2021 fromhttps://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Quality-And-Safety-of-Healthcare/Patient-Safety/Calendar-of-Events/Patient-Safety-Awareness-Week-PSAW

2FDA-FDA MedWatch and Patient Safety retrieved on 03/14/2021 from  https://www.fda.gov/media/89040/download

 

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This